Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia reported Q1 total revenue of $268 million, up 10% year-over-year, driven by 20% growth in DAYBUE sales to $101 million and 6% growth in NUPLAZID sales to $167 million. The company reaffirmed its full-year 2026 financial guidance, including total revenue of $1.22 to $1.28 billion, and remains on track for Phase 2 topline data for remlifanserin in Alzheimer's disease psychosis between August and October.
Key figures
- Eps
- 0.02
- Revenue
- 268062000
- Guidance
- Total revenues $1.22B-$1.28B; NUPLAZID sales $760M-$790M; DAYBUE sales $460M-$490M
- Revenue Yoy
- 10%
- Rd expense
- 77000000
- Sga expense
- 171000000
- Daybue sales
- 101000000
- Nuplazid sales
- 167000000
- Cash and investments
- 851000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.